What is the clinical evidence from this study?

Study design: Meta-Analysis. Population: hypercholesterolemia (n=5365). Intervention: Inclisiran vs. Placebo. Primary outcome: Reduction in LDL-C levels (95% CI -41.61 to -22.17).

What does this research mean for the field?

Inclisiran 300 mg significantly reduces LDL-C levels by 31.89 mg/dL and substantially decreases PCSK9 levels in patients with hypercholesterolemia compared to placebo. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To evaluate the efficacy of inclisiran 300 mg in reducing LDL-C and PCSK9 levels among patients with general hypercholesterolemia or heterozygous familial hypercholesterolemia.

March 13, 2026SHILAP Revista de lepidopterologíaOpen Access

Assessing the Impact of Inclisiran on LDL-C and PCSK9 Reduction in Hypercholesterolemic Patients: A Meta-analysis of Cardiovascular Metabolic Prevention

View Full Paper

Ask AI

Bookmark

Key result

Inclisiran 300 mg lowers LDL-C by ~32 mg/dL vs placebo in hypercholesterolemia.

95% CI -41.61 to -22.17
n=5,365

Why the study?

Hypercholesterolemia remains inadequately controlled despite statin use, especially in familial hypercholesterolemia or statin intolerance, prompting evaluation of inclisiran to reduce LDL-C and PCSK9 levels.

Does inclisiran 300 mg reduce LDL-C and PCSK9 levels in patients with general hypercholesterolemia or heterozygous familial hypercholesterolemia compared to placebo?

Key Points

To evaluate the efficacy of inclisiran 300 mg in reducing LDL-C and PCSK9 levels among patients with general hypercholesterolemia or heterozygous familial hypercholesterolemia.
Conducted a systematic search of PubMed, Cochrane, Wiley, and Scopus up to July 2025 to identify randomized controlled trials comparing inclisiran 300 mg with placebo.
Identified 11 multicenter randomized controlled trials comprising approximately 5,365 participants aged 14 to 66 years across countries including the USA, the UK, China, and Japan.
Analyzed absolute mean differences from baseline for primary endpoints of LDL-C and PCSK9 concentrations using random-effects models and subgroup analyses.
Inclisiran reduced LDL-C by a mean difference of -31.89 mg/dL (95% CI: -41.61 to -22.17) in general hypercholesterolemia and -61.47 mg/dL (95% CI: -99.10 to -23.85) in heterozygous familial hypercholesterolemia, with no statistically significant subgroup difference (Chi²=2.23, P = 0.14).
Circulating PCSK9 levels decreased by a mean difference of -65.96 ng/mL (95% CI: -85.14 to -46.79) in general hypercholesterolemia and -56.41 ng/mL (95% CI: -73.46 to -39.37) in heterozygous familial hypercholesterolemia (subgroup difference Chi²=0.53, P = 0.47).

Study Design

Type

Meta-Analysis (n=5,365)

Multicenter

Yes

Structured PICO

Does inclisiran 300 mg reduce LDL-C and PCSK9 levels in patients with general hypercholesterolemia or heterozygous familial hypercholesterolemia compared to placebo?

Population

11 RCTs pooling approximately 5,365 individuals with general hypercholesterolemia or heterozygous familial hypercholesterolemia (HeFH), ages 14 to 66 years, with a balanced distribution between male and female subjects. A substantial portion of the population had established ASCVD or multiple cardiovascular risk factors.

Intervention

Inclisiran 300 mg

Comparator

Placebo

Outcome

Reductions in LDL-C levels and changes in PCSK9 concentrationssurrogate

Inclisiran 300 mg demonstrates consistent and substantial lipid-lowering efficacy by reducing LDL-C and PCSK9 levels across diverse hypercholesterolemic populations, supporting its use as an adjunct or alternative to statins.

Limitations

High heterogeneity among studies (I² >100%)
Limited long-term cardiovascular outcome data
Evaluation based primarily on surrogate lipid endpoints
High heterogeneity (I² >50%)
Mild funnel plot asymmetry indicating potential variability and small-study effects
Fixed dosage of 300 mg restricted evaluation of different dosing strategies
One included trial rated as high risk of bias

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Supports use as statin adjunct or alternative in hypercholesterolemia; reinforces consistent efficacy across pooled RCT populations.

Cite This Study

Nusantara et al. (2026) conducted a meta-analysis in hypercholesterolemia (n=5,365). Inclisiran vs. Placebo was evaluated on Reduction in LDL-C levels (95% CI -41.61 to -22.17). Inclisiran 300 mg significantly reduced LDL-C levels by 31.89 mg/dL in patients with hypercholesterolemia compared to placebo.

synapsesocial.com/papers/69b3aca302a1e69014cce7eb https://doi.org/10.4274/ijca.2026.53315

View Full Paper

Ask AI

Bookmark

Assessing the Impact of Inclisiran on LDL-C and PCSK9 Reduction in Hypercholesterolemic Patients: A Meta-analysis of Cardiovascular Metabolic Prevention

Key Points

Study Design

Structured PICO

Limitations

Discussion

Implication

Cite This Study

Assessing the Impact of Inclisiran on LDL-C and PCSK9 Reduction in Hypercholesterolemic Patients: A Meta-analysis of Cardiovascular Metabolic Prevention

Key Points

Study Design

Structured PICO

Limitations

Discussion

Implication

Cite This Study

Also Consider

Also Consider